EXTRAPOLATION OF DACLATASVIR DOSING RECOMMENDATIONS FROM RITONAVIR BOOSTED PROTEASE INHIBITORSTO COBICISTAT PROTEASE INHIBITORS

被引：0
|
作者：
Gandhi, Y. [1 ]
Wang, Q. [1 ]
Li, W. [1 ]
Eley, T. [1 ]
Zheng, M. [1 ]
LaCreta, F. [1 ]
Bertz, R. [1 ]
Garimella, T. [1 ]
机构：
[1] Bristol Myers Squibb, Princeton, NJ USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 101卷 / S1期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-044
引用
收藏
页码：S65 / S65
页数：1
相关论文
共 50 条
  • [21] Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks
    Kosalaraksa, Pope
    Bunupuradah, Torsak
    Engchanil, Chulapan
    Boonrak, Pitch
    Intasan, Jintana
    Lumbiganon, Pagakrong
    Burger, David
    Ruxrungtham, Kiat
    Schutz, Malte
    Ananworanich, Jintanat
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2008, 27 (07) : 623 - 628
  • [22] Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors
    Justen Manasa
    Vici Varghese
    Sergei L. Kosakovsky Pond
    Soo-Yon Rhee
    Philip L. Tzou
    W. Jeffrey Fessel
    Karen S. Jang
    Elizabeth White
    Thorsteinn Rögnvaldsson
    David A. Katzenstein
    Robert W. Shafer
    Scientific Reports, 7
  • [23] Estimated extent of cross-resistance to ritonavir-boosted protease inhibitors among protease inhibitors-experienced patients: Implications for tipranavir use
    Gallego, O
    De Mendoza, C
    Corral, A
    Barrios, A
    Soriano, V
    AIDS PATIENT CARE AND STDS, 2005, 19 (02) : 67 - 69
  • [24] Coadministration of boceprevir with ritonavir-boosted HIV protease inhibitors could reduce drugs' effectiveness
    不详
    FORMULARY, 2012, 47 (03) : 105 - +
  • [25] Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors
    Manasa, Justen
    Varghese, Vici
    Pond, Sergei L. Kosakovsky
    Rhee, Soo-Yon
    Tzou, Philip L.
    Fessel, W. Jeffrey
    Jang, Karen S.
    White, Elizabeth
    Rognvaldsson, Thorsteinn
    Katzenstein, David A.
    Shafer, Robert W.
    SCIENTIFIC REPORTS, 2017, 7
  • [26] Neurocognitive Performance in Ritonavir-boosted Protease Inhibitor Monotherapy
    Carvalhal, Adriana
    CLINICAL INFECTIOUS DISEASES, 2016, 63 (02) : 265 - 267
  • [27] Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir
    Martinez, Esteban
    D'Albuquerque, Polyana M.
    Llibre, Josep M.
    Gutierrez, Felix
    Podzamczer, Daniel
    Antela, Antonio
    Berenguer, Juan
    Domingo, Pere
    Moreno, Xabier
    Perez, Ignacio
    Pich, Judit
    Gatell, Jose M.
    AIDS, 2012, 26 (18) : 2315 - 2326
  • [28] Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients
    Scott, JD
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (08) : 809 - 815
  • [29] The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors
    Fox, Zoe V.
    Geretti, Anna Maria
    Kjaer, Jesper
    Dragsted, Ulrik Bak
    Phillips, Andrew N.
    Gerstoft, Jan
    Staszewski, Schlomo
    Clotet, Bonaventura
    von Wyl, Viktor
    Lundgren, Jens D.
    AIDS, 2007, 21 (15) : 2033 - 2042
  • [30] Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice
    Costarelli, Silvia
    Cozzi-Lepri, Alessandro
    Lapadula, Giuseppe
    Bonora, Stefano
    Madeddu, Giordano
    Maggiolo, Franco
    Antinori, Andrea
    Gori, Andrea
    D'Arminio-Monforte, Antonella
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2014, 17 : 56 - 57
12345